表紙：神経性過食症治療の世界市場：治療タイプ、投与経路、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

市場調査レポート

商品コード

1085798

神経性過食症治療の世界市場：治療タイプ、投与経路、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment and Non-drug Treatment ), by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月26日 | 発行: Coherent Market Insights

| ページ情報: 英文 156 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 701,325円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,090,950円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,558,500円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.85円

全表示
概要
目次

概要

サンプル依頼リストに入れる

当レポートでは、世界の神経性過食症治療市場について調査分析し、市場概要、市場力学、動向、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

企業プロファイル
- Allergan, Inc.
- Eli Lilly and Company
- AstraZeneca plc
- Alembic Pharmaceuticals Ltd
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Johnson &Johnson Services, Inc.
- Dr. Reddy's Laboratories Limited
- Lupin Pharmaceuticals, Inc.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
アナリストの見解

第10章セクション

Product Code: CMI4323

Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.

Market Dynamics

Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.

Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.

Key features of the study:

This report provides an in-depth analysis of global bulimia nervosa treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

It profiles leading players in the global bulimia nervosa treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market

Detailed Segmentation:

Global Bulimia Nervosa Treatment Market, By Treatment Type:
- Drug Treatment
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
- Non-drug Treatment
Nutritional Therapy
Behavioral Therapy
Others
Global Bulimia Nervosa Treatment Market, By Route of Administration:
- Oral
- Intravenous
- Others
Global Bulimia Nervosa Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Bulimia Nervosa Treatment Market, By Region:
- North America
By Country
- U.S.
- Canada
By Treatment Type:
- Drug Treatment
  - Selective Serotonin Reuptake Inhibitor (SSRI)
  - Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  - Benzodiazepines
  - Tricyclic Antidepressants
  - Others
- Non-Drug Treatment
  - Nutritional Therapy
  - Behavioral Therapy
  - Others
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
By Treatment Type:
- Drug Treatment
  - Selective Serotonin Reuptake Inhibitor (SSRI)
  - Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  - Benzodiazepines
  - Tricyclic Antidepressants
  - Others
- Non-Drug Treatment
  - Nutritional Therapy
  - Behavioral Therapy
  - Others
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
By Treatment Type:
- Drug Treatment
  - Selective Serotonin Reuptake Inhibitor (SSRI)
  - Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  - Benzodiazepines
  - Tricyclic Antidepressants
  - Others
- Non-Drug Treatment
  - Nutritional Therapy
  - Behavioral Therapy
  - Others
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
By Treatment Type:
- Drug Treatment
  - Selective Serotonin Reuptake Inhibitor (SSRI)
  - Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  - Benzodiazepines
  - Tricyclic Antidepressants
  - Others
- Non-Drug Treatment
  - Nutritional Therapy
  - Behavioral Therapy
  - Others
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
By Country:
- GCC
- Israel
- Rest of Middle East
By Treatment Type:
- Drug Treatment
  - Selective Serotonin Reuptake Inhibitor (SSRI)
  - Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  - Benzodiazepines
  - Tricyclic Antidepressants
  - Others
- Non-Drug Treatment
  - Nutritional Therapy
  - Behavioral Therapy
  - Others
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
By Country/Region:
- South Africa
- Central Africa
- North Africa
By Treatment Type:
- Drug Treatment
  - Selective Serotonin Reuptake Inhibitor (SSRI)
  - Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  - Benzodiazepines
  - Tricyclic Antidepressants
  - Others
- Non-Drug Treatment
  - Nutritional Therapy
  - Behavioral Therapy
  - Others
By Route of Administration
- Oral
- Intravenous
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
Allergan, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Eli Lilly and Company
AstraZeneca plc
Alembic Pharmaceuticals Ltd
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Pfizer Inc.
Johnson & Johnson Services, Inc.
Dr. Reddy's Laboratories Limited
Lupin Pharmaceuticals, Inc.
Aurobindo Pharma
Zydus Cadila
Apotex Inc.
Teva Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Epidemiology
Key Developments
Regulatory Scenario
PEST Analysis
Product launches
Acquisition and Merger Scenario

4. Global Bulimia Nervosa Treatment Market - Impact of Coronavirus (Covid - 19) Pandemic

During COVID-19 Market Situation
Supply Side and Demand Side Analysis
Impact of COVID-19 on Depression and Eating Disorders
Government Initiatives to Combat COVID-19

5. Global Bulimia Nervosa Treatment Market, By Treatment Type , 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Drug Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Selective Serotonin Reuptake Inhibitor (SSRI)
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Benzodiazepines
Tricyclic Antidepressants
Others
Non-drug Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Nutritional Therapy
Behavioral Therapy
Others

6. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Bulimia Nervosa Treatment Market, By Region, 2017 - 2028 (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Treatment Type , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
Latin America
- Market Size and Forecast, By Treatment Type , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Market Size and Forecast, By Treatment Type , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Treatment Type , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Treatment Type , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Treatment Type , 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa

9. Competitive Landscape

Company Profiles
- Allergan, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Alembic Pharmaceuticals Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Dr. Reddy's Laboratories Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Lupin Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Aurobindo Pharma
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Apotex Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
Analyst Views

10. Section

References
Research Methodology
About us and Sales Contact

神経性過食症治療の世界市場：治療タイプ、投与経路、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment and Non-drug Treatment ), by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・規制・動向分析

第4章世界の神経性過食症治療市場：コロナウイルス（COVID-19）パンデミックの影響

第5章世界の神経性過食症治療市場：治療タイプ別（2017年～2028年）

第6章世界の神経性過食症治療市場：投与経路別（2017年～2028年）

第7章世界の神経性過食症治療市場：流通チャネル別（2017年～2028年）

第8章世界の神経性過食症治療市場：地域別（2017年～2028年）

第9章競合情勢

第10章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

"" marked represents similar segmentation in other categories in the respective section.*

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Bulimia Nervosa Treatment Market - Impact of Coronavirus (Covid - 19) Pandemic

5. Global Bulimia Nervosa Treatment Market, By Treatment Type , 2017 - 2028 (US$ Million)

6. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

7. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

8. Global Bulimia Nervosa Treatment Market, By Region, 2017 - 2028 (US$ Million)

9. Competitive Landscape

10. Section

神経性過食症治療の世界市場：治療タイプ、投与経路、流通チャネル、地域別 - 規模、シェア、見通し、機会分析（2022年～2028年）

Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment and Non-drug Treatment ), by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学・規制・動向分析

第4章 世界の神経性過食症治療市場：コロナウイルス（COVID-19）パンデミックの影響

第5章 世界の神経性過食症治療市場：治療タイプ別（2017年～2028年）

第6章 世界の神経性過食症治療市場：投与経路別（2017年～2028年）

第7章 世界の神経性過食症治療市場：流通チャネル別（2017年～2028年）

第8章 世界の神経性過食症治療市場：地域別（2017年～2028年）

第9章 競合情勢

第10章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Bulimia Nervosa Treatment Market - Impact of Coronavirus (Covid - 19) Pandemic

5. Global Bulimia Nervosa Treatment Market, By Treatment Type , 2017 - 2028 (US$ Million)

6. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2017 - 2028 (US$ Million)

7. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Million)

8. Global Bulimia Nervosa Treatment Market, By Region, 2017 - 2028 (US$ Million)

9. Competitive Landscape

10. Section

第1章調査目的・前提条件

第2章市場概要

第3章市場力学・規制・動向分析

第4章世界の神経性過食症治療市場：コロナウイルス（COVID-19）パンデミックの影響

第5章世界の神経性過食症治療市場：治療タイプ別（2017年～2028年）

第6章世界の神経性過食症治療市場：投与経路別（2017年～2028年）

第7章世界の神経性過食症治療市場：流通チャネル別（2017年～2028年）

第8章世界の神経性過食症治療市場：地域別（2017年～2028年）

第9章競合情勢

第10章セクション

"" marked represents similar segmentation in other categories in the respective section.*